Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (351-360 of 362) with videos related to

Pageof 37
Sort By:
Circulation|April 17, 2026
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry AnalysisRobert Przybylski, Gabrielle Norrish, Brian Claggett, et al.
The New England Journal of Medicine|September 3, 2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionScott D Solomon, John J V McMurray, Inder S Anand, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Circulation|June 22, 2026
Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry AnalysisRobert Przybylski, Gabrielle Norrish, Brian Claggett, et al.
JAMA Cardiology|June 17, 2026
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical TrialGregory D Lewis, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Circulation|March 31, 2022
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart FailureBarry A Borlaug, John Blair, Martin W Bergmann, et al.
Journal of the American College of Cardiology|May 20, 2026
Sex and Age Specific Genetic Risk Across the Dilated and Arrhythmogenic Cardiomyopathy Spectrum: Insights From the SHaRe RegistrySophie L V M Stroeks, Nicole K Bart, Joseph Rossano, et al.
The New England Journal of Medicine|August 26, 2022
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D Solomon, John J V McMurray, Brian Claggett, et al.
Circulation. Genomic and Precision Medicine|July 8, 2026
Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter RegistryMaria Perotto, Cinzia Radesich, Alessia Paldino, et al.
Pageof 37

Showing results (351-360 of 362) with videos related to

Sort By:
Pageof 37
Circulation|April 17, 2026
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry AnalysisRobert Przybylski, Gabrielle Norrish, Brian Claggett, et al.
The New England Journal of Medicine|September 3, 2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionScott D Solomon, John J V McMurray, Inder S Anand, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Circulation|June 22, 2026
Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry AnalysisRobert Przybylski, Gabrielle Norrish, Brian Claggett, et al.
JAMA Cardiology|June 17, 2026
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical TrialGregory D Lewis, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Circulation|March 31, 2022
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart FailureBarry A Borlaug, John Blair, Martin W Bergmann, et al.
Journal of the American College of Cardiology|May 20, 2026
Sex and Age Specific Genetic Risk Across the Dilated and Arrhythmogenic Cardiomyopathy Spectrum: Insights From the SHaRe RegistrySophie L V M Stroeks, Nicole K Bart, Joseph Rossano, et al.
The New England Journal of Medicine|August 26, 2022
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D Solomon, John J V McMurray, Brian Claggett, et al.
Circulation. Genomic and Precision Medicine|July 8, 2026
Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter RegistryMaria Perotto, Cinzia Radesich, Alessia Paldino, et al.
Pageof 37